国际妇产科学杂志2016，Vol.43Issue(5)：515-518,4.
PARP抑制剂在卵巢癌治疗中的研究进展
Research Progress in Poly ADP-ribose Polymerase Inhibitors for Ovarian Cancer Treatment
皮如玉 1李佳蕊2
作者信息
- 1. 200092 上海交通大学医学院附属新华临床医学院
- 2. 上海交通大学附属新华医院妇科
- 折叠
摘要
Abstract
Ovarian cancer is a malignant cancer with insidious onset, and it remains the leading cause of death from gynecological malignancies. Most ovarian cancer patients die of recurrences and drug-resistance. Poly ADP-ribose polymerase (PARP) inhibitors emerge as a new class of targeted agents for ovarian cancer. PARP inhibitors can inhibit PARP enzyme as target in BRCA mutation-positive cells. With a number of clinical trials have shown, PARP inhibitors have anti-cancer effect on ovarian cancer with BRCA mutations. And the adverse effects are well tolerated. As clinical trials shown, PARP inhibitors prolong significantly the progress free survival of ovarian cancer patients with BRCA deficiency. In addition, PARP inhibitors are most active in platinum-sensitive, BRCA mutation-positive ovarian cancer. This review discusses the mechanism of PARP inhibitors as well as the clinical development of this class of anti-cancer agents in ovarian cancer treatment.关键词
聚ADP核糖聚合酶类/卵巢肿瘤/基因,BRCA1/基因,BRCA2/药物疗法Key words
Poly(ADP-ribose) polymerases/Ovarian neoplasms/Genes,BRCA1/Genes,BRCA2/Drug therapy引用本文复制引用
皮如玉,李佳蕊..PARP抑制剂在卵巢癌治疗中的研究进展[J].国际妇产科学杂志,2016,43(5):515-518,4.
